Patients Exploring the role of pharmacy and self-care in the fight ag... Globally, the incidence of fatty liver disease is increasing at a concerning rate, yet, the solution could be simple.
R&D How clinical research is zeroing in on fatty liver disease Americans’ livers are becoming increasingly unhealthy.
News 89bio shows its NASH hand, boosting FGF21 concept Positive phase 2b results on liver fibrosis follow similar data with a rival drug from Akero.
News Akero rockets as NASH drug hits targets in phase 2b trial A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective
Patients Fatty liver disease: With little early detection, more chall... For most of my adult life, I had been the typical American fat guy, gaining a pound or two a year and thinking little of it.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends